Literature DB >> 10225935

Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen.

B Baras1, M A Benoit, L Dupré, O Poulain-Godefroy, A M Schacht, A Capron, J Gillard, G Riveau.   

Abstract

The purpose of this work was to assess the immunogenicity of a single nasal or oral administration of recombinant 28-kDa glutathione S-transferase of Schistosoma mansoni (rSm28GST) entrapped by poly(lactide-co-glycolide) (PLG)- or polycaprolactone (PCL)-biodegradable microparticles. Whatever the polymer and the route of administration used, the equivalent of 100 microg of entrapped rSm28GST induced a long-lasting and stable antigen-specific serum antibody response, with a peak at 9 to 10 weeks following immunization. Isotype profiles were comparable, with immunoglobulin G1 being the predominant isotype produced. The abilities of specific antisera to neutralize the rSm28GST enzymatic activity have been used as criteria of immune response quality. Pooled 10-week sera from mice receiving PLG microparticles by the nasal or oral route neutralized the rSm28GST enzymatic activity, whereas sera of mice receiving either PCL microparticles, free rSm28GST, or empty microparticles inefficiently neutralized this enzymatic activity. Finally, this study shows that a single administration of these microparticles could provide distinct and timely release pulses of microencapsulated antigen, which might greatly facilitate future vaccine development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225935      PMCID: PMC116018     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Biodegradable microspheres as a vaccine delivery system.

Authors:  J H Eldridge; J K Staas; J A Meulbroek; J R McGhee; T R Tice; R M Gilley
Journal:  Mol Immunol       Date:  1991-03       Impact factor: 4.407

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Evidence for enhancement of IgG1 subclass expression in mice polyvaccinated with radiation-attenuated cercariae of Schistosoma mansoni and the role of this isotype in serum-transferred immunity.

Authors:  V Delgado; D J McLaren
Journal:  Parasite Immunol       Date:  1990-01       Impact factor: 2.280

4.  Vaccines for the Third World.

Authors:  B R Bloom
Journal:  Nature       Date:  1989-11-09       Impact factor: 49.962

5.  Assays for differentiation of glutathione S-transferases.

Authors:  W H Habig; W B Jakoby
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

6.  A purified 28,000 dalton protein from Schistosoma mansoni adult worms protects rats and mice against experimental schistosomiasis.

Authors:  J M Balloul; J M Grzych; R J Pierce; A Capron
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

7.  Release of human serum albumin from poly(lactide-co-glycolide) microspheres.

Authors:  M S Hora; R K Rana; J H Nunberg; T R Tice; R M Gilley; M E Hudson
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

8.  Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate.

Authors:  H Okada; Y Inoue; T Heya; H Ueno; Y Ogawa; H Toguchi
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

9.  A monoclonal antibody blocking the Schistosoma mansoni 28-kDa glutathione S-transferase activity reduces female worm fecundity and egg viability.

Authors:  C B Xu; C Verwaerde; J M Grzych; J Fontaine; A Capron
Journal:  Eur J Immunol       Date:  1991-08       Impact factor: 5.532

10.  The glutathione transferase activity and tissue distribution of a cloned Mr28K protective antigen of Schistosoma mansoni.

Authors:  J B Taylor; A Vidal; G Torpier; D J Meyer; C Roitsch; J M Balloul; C Southan; P Sondermeyer; S Pemble; J P Lecocq
Journal:  EMBO J       Date:  1988-02       Impact factor: 11.598

View more
  7 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae.

Authors:  L Goetsch; A Gonzalez; H Plotnicky-Gilquin; J F Haeuw; J P Aubry; A Beck; J Y Bonnefoy; N Corvaïa
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

Review 3.  Schistosomiasis in the People's Republic of China: prospects and challenges for the 21st century.

Authors:  A G Ross; A C Sleigh; Y Li; G M Davis; G M Williams; Z Jiang; Z Feng; D P McManus
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 4.  Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.

Authors:  Akhilesh Kumar Shakya; Kutty Selva Nandakumar
Journal:  J R Soc Interface       Date:  2013-02       Impact factor: 4.118

5.  Biodegradable nanoparticle-entrapped vaccine induces cross-protective immune response against a virulent heterologous respiratory viral infection in pigs.

Authors:  Varun Dwivedi; Cordelia Manickam; Basavaraj Binjawadagi; Dechamma Joyappa; Gourapura J Renukaradhya
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

Review 6.  Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation.

Authors:  Gourapura J Renukaradhya; Balaji Narasimhan; Surya K Mallapragada
Journal:  J Control Release       Date:  2015-09-26       Impact factor: 9.776

7.  Pathogenicity and immune response measured in mice following intranasal challenge with enterotoxigenic Escherichia coli strains H10407 and B7A.

Authors:  Wyatt Byrd; Steven R Mog; Frederick J Cassels
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.